Authors

Guru P. Sonpavde, MD, is the medical director for Genitourinary (GU) Oncology, assistant director of the Clinical Research Unit, and the Christopher K. Glanz Chair for Bladder Cancer Research at AdventHealth Cancer Institute.

Latest:

Dr Sonpavde on OS Data With Ipilimumab/Nivolumab in Previously Untreated, Advanced Urothelial Carcinoma

Guru P. Sonpavde, MD, details overall survival data with ipilimumab/nivolumab vs gemcitabine/platinum in previously untreated, advanced urothelial cancer.

Guru Sonpavde, MD

Latest:

Advancing Multidisciplinary Collaboration in MIBC Management

Experts discuss the potential of ctDNA in optimizing bladder cancer treatment, questioning overtreatment and exploring personalized therapy approaches.

Gustavo Fernandez, MD

Latest:

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Gustavo Olivera PhD

Latest:

Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation

Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.

Guy Jerusalem, MD, PhD

Latest:

Dr. Jerusalem on Trastuzumab Deruxtecan in HER2+ Breast Cancer

Guy Jerusalem, MD, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Guy Young, MD

Latest:

Dr. Young on the Challenges of Using Anticoagulants in Children With Cancer

Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, discusses the challenges of using anticoagulants in children with cancer.

Gyorgy Petrovics, PhD

Latest:

Gyorgy Petrovics on Frequency of BRCA Mutations in African American Prostate Cancer Patients

Gyorgy Petrovics, PhD, associate director, Center for Prostate Disease Research (CPDR), research associate professor in the department of surgery at the Uniformed Services University of the Health Sciences (USUHS), discusses BRCA1 and BRCA2 mutations in African American prostate cancer patients.

Gypsyamber DSouza, PhD

Latest:

Dr. D'Souza on Screening for HPV-Related Cancers

Gypsyamber D'Souza, PhD, MPH, MS, an associate professor of epidemiology at Johns Hopkins University, comments on screening for HPV-related cancers.

H. Jack West, MD

Latest:

Final Thoughts on Effective Therapy and Financial Toxicity

Experts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.

H. Jack West, MD, Swedish Cancer Institute

H. Omer Ikizler, MD

Latest:

PrimeMD, a Pain Reporting Smartphone Application for Patients Undergoing Head and Neck Radiation

A feasibility study of a smartphone application that patients undergoing radiation therapy for head and neck cancer can use to regularly report mucositis symptoms.

Habte A. Yimer, MD

Latest:

Dr. Yimer on Long-Term Proteasome Inhibition in Newly Diagnosed Myeloma

Habte A. Yimer, MD, of Texas Oncology, discusses a real-world study evaluating the long-term use of proteasome inhibition in patients with multiple myeloma, and transitioning from bortezomib (Velcade) to ixazomib (Ninlaro).

Haejin In, MD, MPH, MBA, FACS

Latest:

Dr In on the Importance of Early Cancer Prevention Strategies in Gastric Cancer

Haejin In, MD, MPH, MBA, FACS, FSSO, discusses the importance of identifying individuals at high risk for developing gastric cancer.

Hagen F. Kennecke, MD, MHA, FRCPC

Latest:

Dr. Kennecke on Available Treatments for GEP-NETs

Hagen F. Kennecke, MD, MHA, FRCPC, discusses the treatments available for patients with advanced gastroenteropancreatic neuroendocrine tumors.

Hagop M. Kantarjian, MD

Latest:

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Dr. Hagop Kantarjian presents the Phase I/II SAVE trial results, showcasing the promising efficacy and safety of the all-oral combination of revumenib, decitabine/cedazuridine, and venetoclax in relapsed/refractory AML, achieving high response rates and MRD negativity in heavily pretreated patients.

Haiying Cheng, MD

Latest:

Dr. Cheng Discusses RICTOR Amplification in Lung Cancer

Haiying Cheng, MD, medical oncologist, Montefiore Einstein Center for Cancer Care, assistant professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, discuses RICTOR amplification in patients with lung cancer.

Hak Choy, MD

Latest:

Dr. Choy Discusses Therapy for Oligometastatic Lung Cancer

Hak Choy, MD, Nancy B. & Jake L. Hamon Distinguished Chair in Therapeutic Oncology Research, Department of Radiation Oncology, UT Southwestern Medical Center, discuses therapy for patients with oligometastatic lung cancer.

Halle Moore, MD

Latest:

Dr. Moore on the Use of Preventive Anastrozole Versus Tamoxifen in DCIS

Halle Moore, MD, discusses the use of preventive anastrozole versus tamoxifen in ductal carcinoma in situ.

Hanmath J Neboori, MD

Latest:

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

Hannah Kent-Ritchie, PhD

Latest:

Experts Give Advice on How to Plan a Successful Lung Cancer Screening Program

Screening high-risk individuals for lung cancer with low-dose tomography is an effective and recommended approach for reducing mortality from the condition. That said, planning a lung cancer screening program can be challenging, as a successful program requires strategic multidisciplinary.